Manuel David Gil-Sierra

7PUBLICATIONS
2CO-AUTHORS
Molecular targetsGene and molecular therapyHaematological tumoursMedical infection agents (incl. prions)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 14, 2023
New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations.

Gil-Sierra Manuel David, Briceño-Casado Maria Del Pilar, Moreno-Ramos Cristina

|Mar 21, 2022
Belantamab mafodotin for relapsed or refractory multiple myeloma.

Manuel David Gil-Sierra, Maria Del Pilar Briceño-Casado

|Jan 14, 2022
Clinical and pharmacoeconomic impact of subgroup analysis in onco-hematological patients.

Manuel David Gil-Sierra, Maria Del Pilar Briceño-Casado, Marina Sánchez-Hidalgo

|Nov 30, 2021
Daratumumab-based therapies in transplant-ineligible patients with untreated multiple myeloma and hepatic dysfunction: A systematic review of subgroup analyses.

Manuel David Gil-Sierra, Maria Del Pilar Briceño-Casado, Silvia Fénix-Caballero

|Aug 23, 2021
Use of docetaxel in low- and high-burden metastatic hormone-sensitive prostate cancer: A systematic review and assessment of subgroup analyses.

Manuel David Gil-Sierra, Emilio Jesus Alegre-Del Rey, Catalina Alarcon de la Lastra-Romero

|Mar 08, 2020
Network meta-analysis of first-line treatments in transplant-ineligible multiple myeloma patients.

Manuel David Gil-Sierra, Vicente Gimeno-Ballester, Silvia Fenix-Caballero

Pageof 2